FrancophonIA/ELRC3.0 huggingface dataset:
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymtomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Maltese: F'pazjenti infettati bl-HIV, li meta tinbeda l-kura antiretrovirali kombinata (CART), ikollhom immunità defiċjenti ħafna, tista' tirriżulta reazzjoni infjammatorja għall-patoġeni li ma jikkaġunawx sintomi jew li huma opportunistiċi residwali, li tikkaġuna kundizzjonijiet kliniċi serji, jew aggravar tas-sintomi.
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Maltese: Pazjenti b'epatite kronika B jew Ċ u kkurati b'terapija antiretrovirali kombinata qegħdin f'riskju akbar ta' reazzjonijiet avversi relatati mal-fwied, li huma serji ħafna u potenzjalment fatali.
English: Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets Approx 15.0 mm x 8.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR4' on one side of the tablet and plain on the other side.
Maltese: Lopinavir/Ritonavir Mylan 100 mg/25 mg pilloli miksija b'rita huma ta 'lewn abjad, miksija b'rita, ovalojdi, bikonvessi u b'tarf imżerżaq, imnaqqxa b'‘MLR4 'fuq naħa waħda tal-pillola u xejn fuq innaħa l-oħra.
English: A series of blood samples were collected pre-dose and at intervals over the course of 12 hours in trimester 2 and trimester 3, at birth, and 4-6 weeks postpartum (in women who continued treatment postdelivery) for pharmacokinetic analysis of total and unbound levels of plasma lopinavir concentrations.
Maltese: Serje ta 'kampjuni tad-demm inġabru qabel id-doża u f'intervalli matul il-kors ta ' 12-il siegħa fi trimestru 2 u trimestru 3, waqt il-ħlas, u 4-6 ġimgħat wara l-ħlas (f'nisa li komplew ilkura wara l-ħlas) għal analiżi farmakokinetika tal-livelli totali u mhux marbuta tal-konċentrazzjonijiet ta 'lopinavir fil-plażma.
English: The concomitant administration of Lopinavir/Ritonavir Mylan and ranolazine is contraindicated (see section 4.3).
Maltese: L-għoti flimkien ta' Lopinavir/Ritonavir Mylan u ranolazine huwa kontraindikat (ara sezzjoni 4.3).
English: The effects of lopinavir/ritonavir (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of lopinavir/ritonavir of 48 to 360 weeks duration.
Maltese: HIV RNA u għadd ta' CD4+ T-cell) ġew investigati fi studji kkontrollat ta' lopinavir/ritonavir li damu 48 għal 360 ġimgħa.
English: In addition, virologic response was observed in 91% (21/23), 71% (15/21) and 33% (2/6) patients with 0 − 5, 6 − 7, and 8
Maltese: Barraminnhekk, rispons viroloġiku ġie osservat f'91% (21/23), f'71% (15/21) u fi 33% (2/6) tal-pazjenti b' 0−5, 6−7, u 8−10 mutazzjonijiet tal-mutazzjonijiet hawn fuq imsemmija fil-protejaż ta' l-HIV assoċjat mas-suxxettibilità in vitro imnaqqsa għal liponavir.
English: At week 48, the efficacy and safety with twice-daily dosing (n=87) in the paediatric population given lopinavir/ritonavir 100 mg/25 mg tablets was consistent with the efficacy and safety findings in previous adult and paediatric studies using lopinavir/ritonavir twice daily.
Maltese: Fit-48 ġimgħa, l-effikaċja u s-sigurtà b'dożaġġ ta' darbtejn kuljum (n = 87) fil-popolazzjoni pedjatrika mogħtija pilloli ta' lopinavir/ritonavir 100 mg/25 mg kienu konsistenti mas-sejbiet dwar l-effikaċja u s-sigurtà preċedenti fl-adulti u ma' studji pedjatriċi li jużaw lopinavir/ritonavir darbtejn kuljum.
English: Further stratification within each group was 1:1 (tablet versus.
Maltese: Stratifikazzjoni addizzjonali f'kull grupp kienet fi proporzjon ta ' 1:1 (pillola kontra kapsula ratba).
English: Lopinavir/Ritonavir Mylan contains sodium
Maltese: Lopinavir / Ritonavir Mylan fih sodju
English: Other side effects that have been reported with lopinavir/ritonavir: yellowing of the skin or whites of eyes (jaundice), severe or life threatening skin rashes and blisters (Stevens-Johnson syndrome and erythema multiforme).
Maltese: Effetti oħra mhux mixtieqa li ġew irrapurtati b'lopinavir/ritonavir: ġilda li tisfar jew l-abjad tal-għajnejn li jisfar (jaundice), Raxx u nfafet gravi jew ta' periklu għal ħajtek (sindromu ta' Stevens-Johnson u erythema multiforme).
English: The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1).
Maltese: L-għażla ta' lopinavir/ritonavir għall-kura ta' pazjenti infettati b'HIV-1 li kienu diġà ġew trattati b'impedituri protejaż, għandha tkun ibbażata fuq testijiet individwali ta' reżistenza virali u fuq l-istorja ta' kura tal-pazjenti (ara sezzjoni 4.4 u 5.1).
English: AUC: ↑ 153% Cmax: ↑ 55%
Maltese: AUC: ↑ 153%
English: Lopinavir/Ritonavir Mylan tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
Maltese: Lopinavir/ritonavir fih lopinavir u ritonavir, it-tnejn li huma impedituri ta' l-iżoforma ta' P450, CYP3A.
English: The use of a once daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice daily dosing.
Maltese: L-użu ta ' dożaġġ ta ' darba kuljum għandu jiġi limitat għal dawk il-pazjenti adulti li jkollhom biss ftit ħafna mutazzjonijiet assoċjati ma ' inibitur tal-protease (PI) (i.e. inqas minn 3 mutazzjonijiet PI b'konformità mar-riżultati tal-provi kliniċi, ara sezzjoni 5.1 għaddeskrizzjoni sħiħa tal-popolazzjoni), u għandu jikkunsidra r-riskju ta ' sostenibbiltà inqas tassoppressjoni viroloġika (ara sezzjoni 5.1) u riskju ogħla ta ' dijarea (ara sezzjoni 4.8) meta mqabbel malistandard rakkomandat ta ' dożaġġ darbtejn kuljum.
English: Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets Each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer.
Maltese: Lopinavir/Ritonavir Mylan 200 mg/50 mg pilloli miksija b'rita Kull pillola miksija b'rita fiha 200 mg ta ' lopinavir koformulata b'50 mg ta ' ritonavir bħala enhancer farmakokinetiku.
English: Adult patients who have not previously taken other antiviral medicines can also take lopinavir/ritonavir tablets once daily as an 800 mg/200 mg dose.
Maltese: Pazjenti adulti li ma kienux ħadu mediċini antiretrovirali oħra qabel, jistgħu jieħdu l-pilloli lopinavir/ritonavir darba kuljum bħala doża ta' 800 mg/200 mg.
English: Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, lopinavir/ritonavir was used in combination with efavirenz or nevirapine.
Maltese: Bħal inibituri oħra ta' nucleoside reverse transcriptase (NRTIs), f'xi ftit studji, lopinavir/ritonavir kien użat ikkombinat ma' efavirenz jew nevirapine.
English: Lopinavir is extensively metabolised by the hepatic cytochrome P450 system, almost exclusively by isozyme CYP3A.
Maltese: Lopinavir huwa, fil-biċċa l-kbira tiegħu, metabolizzat mis-sistema ċitokroma P450 tal-fwied, kważi esklussivament mill-iżożima CYP3A.
English: Multipack: 360 (3 bottles of 120) film-coated tablets
Maltese: 360 (3 fliexken ta '120) pillola miksija b'rita
English: The use of avanafil with Lopinavir/Ritonavir Mylan is contraindicated (see section 4.3).
Maltese: L-użu ta' avanafil ma' Lopinavir/Ritonavir Mylan huwa kontraindikat (ara sezzjoni 4.3).
English: Fosamprenavir (1400 mg BID) (Lopinavir/ritonavir 533/133 mg BID)
Maltese: (Lopinavir/ritonavir 533/133 mg BID)
English: In vitro experiments with human hepatic microsomes indicate that lopinavir primarily undergoes oxidative metabolism.
Maltese: Esperimenti in vitro li saru b'mikrosomi umani tal-fwied jindikaw li, primarjament, lopinavir jgħaddi minn metaboliżmu ossidattiv.
English: They are available in blister multipacks of 120, 120x1 (4 cartons of 30 or 30x1) or 360 (12 cartons of 30) film-coated tablets and in plastic bottles (containing a desiccant, which should not be eaten) of 120 filmcoated tablets and a multipack containing 360 (3 bottles of 120) film-coated tablets.
Maltese: Huma disponibbli f'pakketti multipli bil-folji ta '120, 120x1 (4 kartuni ta '30 jew 30x1) jew 360 (12-il kartuna ta '30) pillola miksija b'rita u fi fliexken tal-plastik (li jkun fihom dessikant, li m'għandux jittiekel) ta '120 pillola miksija b'rita, u pakkett multiplu li jkun fih 360 pillola (3 fliexken ta' 120) pillola miksija b'rita.
English: Uncommon Atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence
Maltese: Aterosklerożi bħal infart mijokardijaku, imblukkar atrioventrikulari, valv tricuspid li ma jaħdimx kif suppost.
English: Anaemia, leucopenia, neutropenia, lymphadenopathy
Maltese: Anemija, lewkopenija, newtropenja, limfadenopatija
English: Multiple dosing of 800/200 mg lopinavir/ritonavir once daily for 2 weeks without meal restriction (n=16) produced a mean ± SD lopinavir peak plasma concentration (Cmax) of 14.8 ± 3.5 μg/ml, occurring approximately 6 hours after administration.
Maltese: Dożaġġ multiplu ta ' 800/200 mg ta ' lopinavir/ritonavir darba kuljum għal ġimagħtejn mingħajr restrizzjonijiet ta ' ikel (n = 16) ipproduċa medja ± SD ta ' konċentrazzjoni massima ta ' lopinavir fil-plażma (Cmax) ta '14.8 ± 3.5 μg/ml, li seħħet bejn wieħed u ieħor 6 sigħat wara l-għoti.
English: The in vitro antiviral activity of lopinavir against 112 clinical isolates taken from patients failing therapy with one or more protease inhibitors was assessed.
Maltese: Ġiet evalwata l-attività antivirali in vitro ta' lopinavir kontra 112 iżolat kliniku meħuda minn pazjenti li ma kinux qegħdin juru rispons għat-terapija b'wieħed jew aktar impeditur protejaż.
English: Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets Approx 18.8 mm x 10.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR3' on one side of the tablet and plain on the other side.
Maltese: Lopinavir/Ritonavir Mylan 200 mg/50 mg pilloli miksija b'rita huma ta 'lewn abjad, miksija b'rita, ovalojdi, bikonvessi u b'tarf imżerżaq, imnaqqxa b'‘MLR3 'fuq naħa waħda tal-pillola u xejn fuq innaħa l-oħra.
English: NAME OF THE MEDICINAL PRODUCT Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets lopinavir/ritonavir
Maltese: TAL-PRODOTT MEDIĊINALI Lopinavir/Ritonavir Mylan 100 mg/25 mg pilloli miksija b'rita lopinavir/ritonavir
English: Concomitant administration with colchicine is contraindicated in patients with renal and/or hepatic impairment (see sections 4.3 and 4.5).
Maltese: Amministrazzjoni b'mod konkomitanti flimkien ma' colchicine huwa kontraindikat, f'pazjenti b'indeboliment fil-kliewi u/jew fil-fwied (ara sezzjonijiet 4.3 u 4.5).
English: NAME OF THE MEDICINAL PRODUCT Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets lopinavir/ritonavir
Maltese: TAL-PRODOTT MEDIĊINALI Lopinavir/Ritonavir Mylan 200 mg/50 mg pilloli miksija b'rita lopinavir/ritonavir
English: The following side effects have been reported by patients who took this medicine.
Maltese: L-effetti sekondarji li ġejjin kienu rrappurtati minn pazjenti li ħadu din il-mediċina.
English: HIV RNA < 400 copies/ml*
Maltese: HIV RNA < 400 kopji/ml* HIV RNA < 50 kopji/ml*†
English: Integrase inhibitor
Maltese: Sindromi ta' Rikostituzzjoni Infjammatorja
English: Concomitant administration of Lopinavir/Ritonavir Mylan with colchicine in patients with renal and/or hepatic impairment is contraindicated due to a potential increase of colchicine-related serious and/or life-threatening reactions such as neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4).
Maltese: L-għoti ta' Lopinavir/Ritonavir Mylan flimkien ma' colchicine f'pazjenti bi b'indeboliment talkliewi u/jew tal-fwied huwa kontraindikat minħabba żieda potenzjali ta' reazzjonijiet serji u / jew periklu għall-ħajja bħal tossiċità newromuskolari relatata ma' colchicine (inkluż rabdomijoliżi) (ara sezzjonijiet 4.3 u 4.4).
English: The dose of maraviroc should be decreased to 150 mg twice daily during co-administration with Lopinavir/Ritonavir Mylan 400/100 mg twice daily.
Maltese: Id-doża ta' maraviroc għanda tiġi mnaqqsa għal-150 mg darbtejn kuljum waqt ko-amministrazzjoni b'Lopinavir/Ritonavir Mylan 400/100 mg darbtejn kuljum.
English: Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets.
Maltese: Lopinavir/Ritonavir Mylan 100 mg/25 mg pilloli miksija b'rita.
English: Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets.
Maltese: Lopinavir/Ritonavir Mylan 200 mg/50 mg pilloli miksija b'rita.
English: The co-administration of riociguat with Lopinavir/Ritonavir Mylan is not recommended (see section 4.4 and refer to riociguat SmPC).
Maltese: L-għoti flimkien ta' riociguat ma' Lopinavir/Ritonavir Mylan mhuwiex irrakkomandat (ara sezzjoni 4.4 u rreferi għall- SmPC ta' riociguat).
English: Lopinavir: ↔ (Relative to 400/100 mg BID administered alone)
Maltese: Lopinavir: ↔ (Relattiv għal 400/100 mg BID meta jingħata waħdu)
English: Protocol defined non-inferiority of once daily dosing compared with twice daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Maltese: In-noninferjorità definita mill-protokoll tad-dożaġġ ta ' darba kuljum meta mqabbla maddożaġġ darbtejn kuljum intweriet jekk il-lower bound tal-intervall ta ' kunfidenza ta ' 95% għaddifferenza fil-proporzjon ta ' individwi li rrispondew (darba kuljum minus darbtejn kuljum) esklużi -12% f'Ġimgħa 48.
English: The pharmacokinetic properties of lopinavir co-administered with ritonavir have been evaluated in healthy adult volunteers and in HIV-infected patients; no substantial differences were observed between the two groups.
Maltese: Il-karatteristiċi farmakokinetiċi ta' lopinavir mgħoti flimkien ma' ritonavir ġew evalwati f'voluntiera adulti f'saħħithom u f'pazjenti infettati bl-HIV; ma' ġew innutati l-ebda differenzi sostanzjali bejn iżżewg gruppi.
English: AUC: ↑ 49-fold Due to CYP3A inhibition by lopinavir/ritonavir.
Maltese: AUC: ↑ 49-darba Minħabba li lopinavir/ritonavir jimpedixxi CYP3A.
English: In post-marketing surveillance through the Antiretroviral Pregnancy Registry, established since January 1989, an increased risk of birth defects exposures with lopinavir/ritonavir has not been reported among over 1000 women exposed during the first trimester.
Maltese: Fis-sorveljanza ta' wara t-tqegħid fis-suq permezz tar-Reġistru tat-tqala antiretrovirali, stabbilit f'Jannar 1989, żieda fir-riskju li jidhru aktar difetti mat-twelid b'lopinavir/ritonavir ma ġewx irrapurtati fost aktar minn 1000 nisa esposti matul l-ewwel tlett xhur.
English: 400/100 mg BID)
Maltese: Fosamprenavir (1400 mg BID)
English: Lopinavir/ritonavir is likely to increase plasma concentrations of medicinal products that are primarily metabolised by CYP3A.
Maltese: Lopinavir/ritonavir x'aktarx li jżid il-konċentrazzjoni fil-plażma ta' prodotti mediċinali li huma primarjament metabolizzati minn CYP3A.
English: AUC: ↑ 11-fold Due to CYP3A inhibition by lopinavir/ritonavir.
Maltese: AUC: ↑ 11-il darba Minħabba li lopinavir/ritonavir jimpedixxi CYP3A.
English: The efficacy data favouring the twice-daily regimen are reinforced by a differential in pharmacokinetic parameters significantly favouring the twice-daily regimen (see section 5.2).
Maltese: Id-dejta dwar l-effikaċja li tiffavorixxi r-reġimen ta' darbtejn kuljum hija msaħħa minn differenzjal fil-parametri farmakokinetiċi li jiffavorixxi b'mod sinifikattiv ir-reġimen ta' darbtejn kuljum (ara sezzjoni 5.2).
English: Fosamprenavir/ ritonavir (700/100 mg BID) (Lopinavir/ritonavir
Maltese: Fosamprenavir/ ritonavir (700/100 mg
English: Isolates retained susceptibility to tipranavir with a median increase of IC50 in baseline and rebound isolates of 1.9- and 1.8-fold, respectively, compared to wild type virus.
Maltese: L-iżolati żammew is-suxxetibilità għal tipranavir b'żieda medjana ta' IC50 fl-iżolati tallinja bażi u f'dawk li marru lura, ta' 1.9 darbiet u 1.8 darbiet aktar, rispettivament, imqabbla ma virus tat-tip mhux ikkultivat.
English: − Haemophilia type A and B as lopinavir/ritonavir might increase the risk of bleeding.
Maltese: - Emofilja tip A u B, peress li lopinavir/ritonavir jista' iżid ir-riskju ta-telf ta' demm.
English: Lopinavir and ritonavir levels may increase on stopping St John's wort.
Maltese: Jista' jkun hemm żieda fil-livelli ta' lopinavir u ritonavir meta jitwaqqaf il-fexfiex tar-raba' (St John's wort).
English: Potential for serious and/or lifethreatening reactions in patients with renal and/or hepatic impairment (see sections 4.4 and 4.5).
Maltese: Potenzjal ta' reazzjonijiet serji u/jew ta' periklu għall-ħajja f'pazjenti b'indeboliment renali u/jew epatiku (ara sezzjonijiet 4.4 u 4.5).
English: The signs of toxicity observed in mice, rats or dogs included decreased activity, ataxia, emaciation, dehydration and tremors.
Maltese: Is-sinjali ta' tossiċità osservati fil-ġrieden, firien jew klieb inkludew tnaqqis fl-attività, atassja, għelubija esaġerata, deidratazzjoni u tregħid.
English: The percentage of patients with confirmed viral rebound ≥50 copies/ml during 48 weeks of follow-up was higher in the paediatric patients receiving lopinavir/ritonavir tablets once daily (12%) than in patients receiving the twice-daily dosing (8%, p = 0.19), mainly due to lower adherence in the once-daily group.
Maltese: Il-perċentwal ta' pazjenti b'rikaduta virali kkonfermata b'anqas minn 50 kopja/ml waqt 48 ġimgħa ta' segwitu kien għola fil-pazjenti pedjatriċi li kienu qed jirċievu pilloli ta' lopinavir/ritonavir darba kuljum (88.2 %) milli f'pazjenti li kienu qed jirċievu ddożaġġ ta' darbtejn kuljum (8%, p = 0.19), prinċipalment minħabba inqas aderenza fil-grupp ta' darba kuljum.
English: The 4-oxo and 4hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity.
Maltese: Il-par epimeriku 4-oxo u 4hydroxymetabolite huma l-metaboliti prinċipali, b'attività antivirali, imma jikkomprendu biss ammonti żgħar ħafna mit-total kollu tar-radjoattività fil-plażma.
English: QD
Maltese: jew
English: In another open-label pharmacokinetic study, 19 HIV-infected pregnant women received lopinavir/ritonavir 400/100 mg twice daily as part of combination antiretroviral therapy during pregnancy from before conception.
Maltese: Fi studju ieħor farmakokinetiku open-label, 19-mara tqila infettati bl-HIV, irċivew lopinavir/ritonavir 400/100 mg darbtejn kuljum bħala parti minn terapija antiretrovirali kombinata matul it-tqala sa minn qabel il-konċepiment.
English: The median fold IC50 of lopinavir for these 18 isolates at baseline and rebound was 6.9- and 63-fold, respectively, compared to wild type virus.
Maltese: It-tinja medjana ta' l-IC50 ta' lopinavir ta' dawn it-18 -il iżolat fil-linja bażi u li marru lura kienet ta' 6.9 darba u 63 darba aktar rispettivament, meta mqabbla mal-virus tat-tip mhux ikkultivat.
English: Paediatric dosing guidelines without concomitant efavirenz or nevirapine* Weight (kg)
Maltese: Linji gwida ta 'dożaġġ pedjatriku mingħajr efavirenz jew nevirapine* mogħtija fl-istess ħin Piż (kg)
English: All patients converted to open-label lopinavir/ritonavir at the 400/100 mg twice daily dose between week 48 and week 72.
Maltese: Il-pazjenti kollha qalbu għal open-label lopinavir/ritonavir fid-doża ta ' 400/100 mg darbtejn kuljum bejn ġimgħa 48 u ġimgħa 72.
English: Ritonavir has been shown to induce metabolic enzymes, resulting in the induction of its own metabolism, and likely the induction of lopinavir metabolism.
Maltese: Dan l-effett jista' jkun ikkawżat mill-induzzjoni tal-metaboliżmu ta' bupropion.
English: − quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder);
Maltese: l-irqad); - pimozide (użati biex jittrattaw skizofrenija); - quetiapine (użat biex jitratta skizofrenja, disturb bipolari u disturb dipressiv maġġuri); - lurasidone (użat biex jittratta dipressjoni);
English: Elbasvir/grazoprevir (50/200 mg QD)
Maltese: Antivirali li jaġixxu b'mod dirett fuq HCV Elbasvir/grazoprevir (50/200 mg QD)
English: Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide and triamcinolone.
Maltese: Rakkomandazzjoni klinika dwar l-għoti ta' prodotti mediċinali oħra flimkien ma' Lopinavir/Ritonavir Mylan jew applikat fl-imnieħer; dan jista' jiġri wkoll b'kortikosterojdi oħra metabbolizzati mill-proċess ta' P450 3A eż budesonide u triamcinolone.
English: − weight gain.
Maltese: Mhux applikabbli.
English: Concomitant use of lopinavir/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and triamcinolone, is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Maltese: L-użu flimkien ta' lopinavir/ritonavir u fluticasone jew glukokortikojdi oħra li huma metabolizzati minn CYP3A4, bħal budesonide u triamcinolone, mhux irrikmandat sakemm il-benefiċċju potenzjali tal-kura ma jkunx ikbar mir-riskju tal-effetti sistemiċi tal-kortikosterojdi, inklużi s-sindromu ta' Cushing u suppressjoni adrenali (ara sezzjoni 4.5).
English: The plasma levels of ritonavir are less than 7% of those obtained after the ritonavir dose of 600 mg twice daily.
Maltese: Il-livelli fil-plażma ta' ritonavir huma inqas minn 7% ta' dawk miksuba wara d-doża ta' ritonavir ta' 600 mg darbtejn kuljum.
English: One-hundred thirteen nelfinavir-treated patients and 74 lopinavir/ritonavir-treated patients had an HIV RNA above 400 copies/ml while on treatment from Week 24 through Week 96.
Maltese: Mija u tlettax il-pazjent trattati b' nelfinavir u 74 pazjent trattati b' lopinavir/ritonavir kellhom HIV RNA il-fuq min 400 kopja/ml waqt li kienu fuq trattament min ġimgħa 24 sa ġimgħa 96.
English: Careful monitoring of adverse effects (notably respiratory depression but also sedation) is recommended when fentanyl is concomitantly administered with Lopinavir/Ritonavir Mylan.
Maltese: Monitoraġġ b'attenzjoni tal-effetti avversi (notevolment dipressjoni respiratorja kif ukoll effett sedattiv) hu rakkomandat meta fentanyl jingħata flimkien ma' Lopinavir/Ritonavir Mylan.
English: AUC: ↑ 295% Cmax: ↑ 97%
Maltese: AUC: ↑ 295%
English: HIV-1 has been passaged in vitro with lopinavir alone and with lopinavir plus ritonavir at concentration ratios representing the range of plasma concentration ratios observed during lopinavir/ritonavir therapy.
Maltese: HIV-1 ġie mgħoddi in vitro ma' lopinavir waħdu u ma' lopinavir flimkien ma' ritonavir fi proporzjonijiet ta' konċentrazzjoni, li jirrappreżentaw il-medda tal-proporzjonijiet ta' konċentrazzjoni fil-plażma osservati waqt it-terapija b'lopinavir/ritonavir.
English: More frequent electrocardiogram monitoring and monitoring of transaminases is recommended (see section 4.4 and refer to the bedaquiline SmPC).
Maltese: Monitoraġġ aktar frekwenti b'elettrokardjogramma u lmonitoraġġ ta' transaminases huwa rrakkomandat (ara sezzjoni 4.4 u rreferi għall-SmPC ta' bedaquiline).